Clinical Trial Update: Access Study of Trametinib for Subjects With Advanced Unresectable (Stage IIIc) or Distant Metastatic (Stage IV) BRAF V600E/K Mutation Positive Cutaneous Melanoma

View source ↗

Summary

This trial update notes that the Access Study of trametinib in advanced unresectable or metastatic BRAF V600E/K-mutant cutaneous melanoma is no longer available…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Melanoma

Drugs mentioned

• Trametinib (trametinib)

Snippet

Sponsor: GlaxoSmithKline | Conditions: Melanoma | Status: NO_LONGER_AVAILABLE